A phase II multicentre double-blind randomised placebo-controlled four-way cross-over dose-range funding study to evaluate efficacy, safety and tolerability of PSD502 in subjects with premature ejaculation (PE).
Phase of Trial: Phase II
Latest Information Update: 06 Jul 2017
At a glance
- Drugs Lidocaine/prilocaine (Primary)
- Indications Premature ejaculation
- Focus Therapeutic Use
- Sponsors Plethora Solutions
- 29 Jan 2010 Planned number of patients changed from 40 to 35 as reported by ISRCTN: Current Controlled Trials.
- 27 Aug 2009 New trial record